NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NRX Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.63+0.03 (+1.15%)
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
26.9%
12M of 43M shares
Institutional holders
47
19 new, 5 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| B Group Capital LLC | 3,000,000 | 12.62% | 13G (passive) | Aug 18, 2025 |
| Amin Nathoo | 1,604,975 | 9.30% | 13G (passive) amendment | Jun 30, 2025 |
| Anson Management GP LLC | 1,179,061 | 7.00% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NRXP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| B Group, Inc. | 4,091,767 | 9.45% | $16.74M | +1,091,767 | 7.86% |
| Vanguard Capital Management LLC | 1,618,159 | 3.74% | $6.62M | +457,975 | 0.00% |
| Ameriprise Financial Inc | 928,728 | 2.15% | $3.80M | New | 0.00% |
| Balyasny Asset Management L.P. | 893,864 | 2.06% | $3.66M | New | 0.00% |
| Citadel Advisors LLC | 680,043 | 1.57% | $2.78M | New | 0.00% |
| AdvisorShares Investments LLC | 659,018 | 1.52% | $2.70M | +238,551 | 0.33% |
| Commonwealth Equity Services, LLC | 454,418 | 1.05% | $1.86M | +56,987 | 0.00% |
| UBS Group AG | 423,115 | 0.98% | $1.73M | +397,888 | 0.00% |
| Geode Capital Management, LLC | 314,659 | 0.73% | $1.29M | +4,547 | 0.00% |
| BlackRock, Inc. | 220,460 | 0.51% | $901.68K | +121,465 | 0.00% |
| Marshall Wace, Llp | 194,580 | 0.45% | $795.83K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 182,718 | 0.42% | $747.32K | +13,138 | 0.00% |
| Jane Street Group, LLC | 119,018 | 0.27% | $486.78K | +74,866 | 0.00% |
| Bleakley Financial Group, LLC | 117,216 | 0.27% | $479.41K | +12 | 0.01% |
| State Street Corp | 116,084 | 0.27% | $474.78K | +29,100 | 0.00% |
| Hrt Financial LP | 100,724 | 0.23% | $411 | New | 0.00% |
| Northern Trust Corp | 62,951 | 0.15% | $257.47K | +19,482 | 0.00% |
| Chicago Partners Investment Group LLC | 46,388 | 0.11% | $190.66K | +11,909 | 0.00% |
| Quadrature Capital Ltd | 43,605 | 0.10% | $178.34K | New | 0.00% |
| One Wealth Management Investment & Advisory Services, LLC | 43,309 | 0.10% | $177.13K | – | 0.19% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 47 | 12M | 26.9% | 19 / 17 | 4 / 5 | 6M | 0M |
| Q1 2026 | 33 | 6M | 14.3% | 11 / 13 | 1 / 4 | 5M | 3M |
| Q4 2025 | 28 | 5M | 12.1% | 7 / 7 | 10 / 3 | 2M | 1M |
| Q3 2025 | 24 | 4M | 9.1% | 4 / 13 | 3 / 5 | 1M | 0M |
| Q2 2025 | 25 | 3M | 6.9% | 5 / 10 | 4 / 2 | 1M | 0M |
| Q1 2025 | 22 | 2M | 5.2% | 4 / 6 | 5 / 7 | 1M | 0M |
| Q4 2024 | 25 | 1M | 2.4% | 10 / 4 | 3 / 3 | 0M | 0M |
| Q3 2024 | 18 | 1M | 1.6% | 4 / 4 | 3 / 4 | 0M | 0M |
| Q2 2024 | 19 | 1M | 1.2% | 19 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NRXP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,267,102 | 2.93% | $5.18M | 0.00% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 659,018 | 1.52% | $2.70M | 6.07% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 291,393 | 0.67% | $1.19M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 131,299 | 0.30% | $580.34K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 104,969 | 0.24% | $429.32K | 0.03% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 48,123 | 0.11% | $212.70K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 30,812 | 0.07% | $136.19K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 21,976 | 0.05% | $97.13K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 21,717 | 0.05% | $88.82K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 15,459 | 0.04% | $63.23K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 7,113 | 0.02% | $29.09K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 4,275 | 0.01% | $13.47K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 634 | 0.00% | $2.59K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1,211 | -0.00% | -$4.95K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan C. Javitt | Chairman and Chief Scientist, Director, 10% owner | 1,516,834 | 3.50% | Sep 10, 2025 |
| Joseph Michael Casper | Chief Operating Officer | – | – | Feb 17, 2026 |
| Michael S. Abrams | Chief Financial Officer | – | – | Feb 11, 2025 |
| Patrick John Flynn | Director | 39,459 | 0.09% | Sep 10, 2025 |
| Chaim Hurvitz | Director | 2,214,793 | 5.12% | Sep 10, 2025 |
| Dennis McBride | Director | – | – | Sep 10, 2025 |
| B Group, Inc. | 10% owner | 3,000,000 | 6.93% | Aug 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan C. Javitt Chairman and Chief Scientist, Director, 10% owner | Dec 17, 2024 | Buy | +40,000 | $1.17 | $46.80K | 84,634 |
| Aaron Gorovitz Director | Aug 30, 2023 | Buy | +35,000 | $0.32 | $11.20K | 105,000 |
| Chaim Hurvitz Director | Aug 30, 2023 | Buy | +70,000 | $0.29 | $20.30K | 570,000 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Aug 23, 2023 | Buy | +100,000 | $0.33 | $33.00K | 446,332 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Aug 22, 2023 | Buy | +200,000 | $0.32 | $64.00K | 346,332 |
| Stephen H. Willard CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2022 | Buy | +50,000 | $1.17 | $58.50K | 50,000 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Dec 16, 2022 | Buy | +30,000 | $1.10 | $33.00K | 46,337 |
| Jonathan C. Javitt Director, 10% owner | Dec 14, 2022 | Gift | −300,000 | – | – | 14,468,329 |
| Jonathan C. Javitt Director, 10% owner | Dec 7, 2022 | Sale | −400,000 | $1.00 | $400.00K | 12,899,997 |
| Daniel C. Javitt 10% owner | Nov 30, 2022 | Sale(10b5-1 plan) | −8,441 | $1.50 | $12.66K | 9,634,793 |
| Daniel C. Javitt 10% owner | Nov 29, 2022 | Sale(10b5-1 plan) | −13,730 | $1.50 | $20.60K | 9,643,234 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.25 | $3.13K | 37,709 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.25 | $3.13K | 37,709 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.24 | $3.10K | 40,209 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +1,750 | $1.25 | $2.19K | 1,750 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.25 | $3.13K | 40,209 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +7,021 | $1.11 | $7.79K | 16,337 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +8,716 | $1.12 | $9.76K | 8,716 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +600 | $1.10 | $660 | 9,316 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +8,716 | $1.12 | $9.76K | 8,716 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +600 | $1.10 | $660 | 9,316 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +7,021 | $1.11 | $7.79K | 16,377 |
| Chaim Hurvitz Director | Nov 18, 2022 | Buy | +40,408 | $1.10 | $44.45K | 500,000 |
| Chaim Hurvitz Director | Nov 18, 2022 | Buy | +40,408 | $1.10 | $44.45K | 500,000 |
| Chaim Hurvitz Director | Nov 17, 2022 | Buy | +171,780 | $1.08 | $185.52K | 459,592 |
| Chaim Hurvitz Director | Nov 17, 2022 | Buy | +171,780 | $1.08 | $185.52K | 459,592 |
| Daniel C. Javitt 10% owner | Nov 17, 2022 | Sale(10b5-1 plan) | −33,018 | $1.05 | $34.67K | 9,656,964 |
| Chaim Hurvitz Director | Nov 16, 2022 | Buy | +287,812 | $0.99 | $284.93K | 287,812 |
| Chaim Hurvitz Director | Nov 16, 2022 | Buy | +287,812 | $0.99 | $284.93K | 287,812 |
| Daniel C. Javitt 10% owner | Nov 16, 2022 | Sale(10b5-1 plan) | −133,719 | $1.02 | $136.39K | 9,689,982 |
| Daniel C. Javitt 10% owner | Nov 11, 2022 | Sale(10b5-1 plan) | −49,200 | $1.01 | $49.69K | 9,823,701 |
| Daniel C. Javitt 10% owner | Jul 29, 2022 | Sale | −784,063 | $1.01 | $791.90K | 9,872,901 |
| Daniel C. Javitt 10% owner | Jul 1, 2022 | Gift | −2,000,000 | – | – | 10,656,964 |
| Daniel C. Javitt 10% owner | Jun 7, 2022 | Sale | −86,459 | $0.65 | $56.20K | 12,656,964 |
| Daniel C. Javitt 10% owner | Jun 6, 2022 | Sale | −115,657 | $0.67 | $77.49K | 12,743,423 |
| Daniel C. Javitt 10% owner | Jun 3, 2022 | Sale | −243,596 | $0.70 | $170.52K | 12,859,080 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Jun 1, 2022 | Buy | +100,000 | $0.58 | $58.00K | 146,332 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Jun 1, 2022 | Buy | +100,000 | $58.00 | $5.80M | 146,332 |
| Robert Besthof Chief Comm. & Patient Officer | Sep 15, 2021 | Sale | −40,000 | $11.76 | $470.40K | 23,710 |
| Alessandra Daigneault General Counsel & Secretary | Sep 2, 2021 | Option exercise | +18,420 | $3.07 | $56.55K | 18,420 |
| Alessandra Daigneault General Counsel & Secretary | Sep 2, 2021 | Option exercise | +13,164 | $3.07 | $40.41K | 31,584 |
| Herbert Raymond McMaster Director | Aug 26, 2021 | Option exercise | +18,300 | $2.22 | $40.63K | 18,300 |
| Alessandra Daigneault General Counsel & Secretary | Aug 23, 2021 | Sale | −33,715 | $13.11 | $442.00K | 0 |
| Alessandra Daigneault General Counsel & Secretary | Aug 19, 2021 | Option exercise | +27,395 | $3.07 | $84.10K | 33,715 |
| Robert Besthof Chief Comm. & Patient Officer | Aug 16, 2021 | Option exercise | +63,710 | $0.20 | $12.74K | 63,710 |
| Daniel C. Javitt 10% owner | Jul 16, 2021 | Gift | −434,594 | – | – | 13,102,676 |
| Daniel C. Javitt 10% owner | Jul 16, 2021 | Gift | −434,594 | – | – | 13,537,270 |
| Patrick John Flynn Director | May 24, 2021 | Award | +362,332 | – | – | 362,332 |
| Patrick John Flynn Director | May 24, 2021 | Award | +35,209 | – | – | 35,209 |
| Patrick John Flynn Director | May 24, 2021 | Award | +35,209 | – | – | 35,209 |
| Chaim Hurvitz Director | May 24, 2021 | Award | +208,443 | – | – | 208,443 |
| Chaim Hurvitz Director | May 24, 2021 | Award | +1,436,350 | – | – | 1,436,350 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +8,336 | – | – | 8,336 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +8,336 | – | – | 8,336 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +8,336 | – | – | 8,336 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +16,678 | – | – | 16,678 |
| Sharon Glied Director | May 24, 2021 | Award | +13,168 | – | – | 13,168 |
| Jonathan C. Javitt Chief Executive Officer, Director, 10% owner | May 24, 2021 | Award | +46,332 | – | – | 46,332 |
| Jonathan C. Javitt Chief Executive Officer, Director, 10% owner | May 24, 2021 | Award | +1,422,000 | – | – | 1,422,000 |
| Jonathan C. Javitt Chief Executive Officer, Director, 10% owner | May 24, 2021 | Award | +13,348,997 | – | – | 13,348,997 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.